Penn Capital Management’s Oxford Immunotec Global OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-457,674
| Closed | -$7.99M | – | 248 |
|
|
2020
Q4 | $7.99M | Sell |
457,674
-460,256
| -50% | -$6.46M | 1.01% | 36 |
|
|
2020
Q3 | $10.7M | Sell |
917,930
-10,254
| -1% | -$136K | 1.36% | 6 |
|
|
2020
Q2 | $12.1M | Sell |
928,184
-13,395
| -1% | -$161K | 1.57% | 4 |
|
|
2020
Q1 | $8.72M | Buy |
941,579
+172,524
| +22% | +$2.41M | 1.44% | 7 |
|
|
2019
Q4 | $12.8M | Buy |
769,055
+382,035
| +99% | +$6.19M | 1.34% | 6 |
|
|
2019
Q3 | $6.44M | Buy |
387,020
+115,082
| +42% | +$1.59M | 0.67% | 55 |
|
|
2019
Q2 | $3.74M | Buy |
271,938
+4,648
| +2% | +$71.1K | 0.37% | 102 |
|
|
2019
Q1 | $4.6M | Sell |
267,290
-35,694
| -12% | -$565K | 0.45% | 80 |
|
|
2018
Q4 | $3.87M | Buy |
302,984
+31,704
| +12% | +$481K | 0.38% | 85 |
|
|
2018
Q3 | $4.4M | Buy |
271,280
+14,254
| +6% | +$204K | 0.33% | 93 |
|
|
2018
Q2 | $3.31M | Buy |
257,026
+43,477
| +20% | +$587K | 0.25% | 116 |
|
|
2018
Q1 | $2.66M | Buy |
213,549
+681
| +0.3% | +$8.29K | 0.21% | 134 |
|
|
2017
Q4 | $2.97M | Buy |
212,868
+54,265
| +34% | +$795K | 0.21% | 133 |
|
|
2017
Q3 | $2.66M | Sell |
158,603
-20,812
| -12% | -$339K | 0.19% | 142 |
|
|
2017
Q2 | $3.02M | Buy |
179,415
+61,080
| +52% | +$913K | 0.22% | 118 |
|
|
2017
Q1 | $1.83M | Buy |
+118,335
| New | +$1.69M | 0.13% | 173 |
|
Penn Capital Management's OXFD Position: Q1 2021 in Review
Penn Capital Management sold out of Oxford Immunotec Global (OXFD) in Q1 2021, closing a stake of 457,674 shares — an estimated $7.99M sold.
Penn Capital Management first reported a position in OXFD in Q1 2017 and held it in 16 quarters. The position peaked at $12.8M in Q4 2019. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Penn Capital Management reported no remaining Oxford Immunotec Global position as of Q1 2021 after selling out during the quarter.
- Penn Capital Management sold 457,674 Oxford Immunotec Global shares in Q1 2021, an estimated $7.99M.
- Penn Capital Management first reported a position in Oxford Immunotec Global in Q1 2017 and held it in 16 quarters.
- Penn Capital Management's Oxford Immunotec Global position peaked at $12.8M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global as of Q1 2021.
Based on Penn Capital Management's 13F filing for Q1 2021, filed 13 May 2021.